Abbott Laboratories
-
Abbott Announces 409th Consecutive Quarterly Dividend
Abbott Laboratories declared its 409th consecutive quarterly dividend, showcasing over a century of consistent financial strength and dedication to shareholders. This enduring payout reflects a robust healthcare portfolio across medical devices, diagnostics, nutrition, and pharmaceuticals, supported by innovation and market leadership. Abbott’s dividend policy signals confidence in its business model and sustained profitability, making it a reliable investment and a key indicator in the healthcare sector.
-
Senseonics Holdings, Inc. Closes Public Offering with Full Exercise of Underwriters’ Over-Allotment Option and Concurrent Private Placement
Senseonics Holdings raised $77.8 million via a public offering (115M shares at $0.50) and a $20.3M private placement from Abbott Laboratories, which acquired a 4.99% stake. The funds will accelerate U.S. commercialization of its Eversense 365, a 12-month implantable glucose monitor, and support innovation. While the capital extends operations through 2026, significant share dilution and low pricing reflect market skepticism. Abbott’s investment signals strategic interest in implantable CGM tech, despite maintaining dominance with its FreeStyle Libre system. Key challenges include securing Medicare coverage and expanding beyond niche medical markets.
